Cargando…

Heterologous expression, purification and function of the extracellular domain of human RANK

BACKGROUND: Receptor activator of NF-κB ligand (RANKL)/RANK signaling essentially functions within the skeletal system, particularly participating in osteoclastogenesis and bone resorption. In addition, this signaling pathway has also been shown to influence tumor progression as well as the developm...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Yilei, Zhan, Yu, Chen, Pengfei, Liu, Zhi, Zhang, Haohao, Liu, Dandan, Zhang, Jie, Yu, Min, Mo, Wei, Zhang, Jun, Zhang, Xiaoren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716252/
https://www.ncbi.nlm.nih.gov/pubmed/29202831
http://dx.doi.org/10.1186/s12896-017-0405-y
Descripción
Sumario:BACKGROUND: Receptor activator of NF-κB ligand (RANKL)/RANK signaling essentially functions within the skeletal system, particularly participating in osteoclastogenesis and bone resorption. In addition, this signaling pathway has also been shown to influence tumor progression as well as the development and function of the immune system. Therefore, blocking the interaction between RANKL and RANK is a new therapeutic approach to prevent bone-related diseases and cancer. RESULTS: The coding sequence encoding the extracellular domain of human RANK (RANK-N) was codon optimized for Pichia pastoris and cloned into the pPIC9K vector, and the recombinant plasmid was then transformed into P. pastoris. The expression of RANK-N protein was confirmed using SDS-PAGE with Coomassie Brilliant Blue stain and western blotting. Recombinant RANK-N protein was purified by a multistep process including ultrafiltration (UF), Sephadex G-50 size-exclusion chromatography and Q-Sepharose Fast Flow ion exchange chromatography, which resulted in a purity >95%. We found that the RANK-N protein can block RANKL-RANK signaling both in vitro and in vivo. Furthermore, using a patient-derived xenograft of human colon cancer, we found that the recombinant RANK-N protein can inhibit the growth of colorectal cancer. CONCLUSIONS: The results show that a simple system to express and purify functional RANK-N protein has been developed. This work has thus laid a foundation for further research and clinical applications of RANK-N protein in treating bone-related diseases or even colorectal cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12896-017-0405-y) contains supplementary material, which is available to authorized users.